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Michele Nichelatti, BSc, PhD,4 Maurizio Postorino, MD,5 and
Giuseppe Quintaliani, MD,6 on behalf of the Italian Dialysis and Transplantation
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Background: Relative survival, a methodology previously used in epidemiologic studies of cancer, com-
pares the observed survival of a patient cohort with expected survival derived from general population life
tables. We examined relative survival in patients treated by long-term dialysis in the Italian Dialysis and
Transplantation Registry in order to determine the prognosis of dialysis patients.
Study Design: Cohort study drawn from a registry.
Setting & Participants: Patients enrolled in the Italian Dialysis and Transplantation Registry.
Factors: Sex, age, primary kidney disease, renal replacement therapy modality, and main comorbid conditions.
Outcomes: Death from any cause.
Measurements: Relative survival ratio (the ratio of observed survival in the population of interest to the
survival expected given the age- and period-specific mortality of the general population) and excess mortality
rate (difference between observed and expected mortality rates).
Results: In January 2000 to December 2008, a total of 27,642 patients were included. The 5-year relative
survival estimate was 55.6% (95% CI, 54.7%-56.5%). The excess mortality rate showed a peak at 3 months (21
deaths/100 patient-years), then decreased, becoming constant from the end of year 1 to year 8, with leveling
off at about 10 deaths/100 patient-years. Older age, systemic diseases, and diabetes showed the strongest
association with excess mortality. Peritoneal dialysis was associated with a lower relative excess risk in only
the first year of treatment.
Limitations: The patient cohort comprises about half the Italian patients beginning dialysis therapy in the
period.
Conclusions: This study highlights the applicability of relative survival methods in dialysis patients. This
measure allows estimation of disease prognosis and severity comparisons among chronic diseases. The
excess mortality rate appears to be a more sensitive and informative measure than the simple proportion of
survivors.
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INDEX WORDS: Relative survival; excess mortality rate; dialysis registry.Mortality in dialysis registries usually is definedby cause-specific or all-cause mortality.1,2 With
the first method, deaths are attributed to a specific
disease, while all other causes are censored. In con-
trast, all-cause (or crude) mortality includes all deaths
within the cohort being studied without distinguishing
those caused by the disease of interest from those
arising from other factors. The main limitation of
cause-specific mortality is that it provides useful infor-
mation only if the registered causes of death are
reliable; this usually is not the case for dialysis regis-
tries or, in general, observational studies.3 However,
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Am J Kidney Dis. 2012;59(6):819-828all-cause survival analysis is limited by the failure to
discriminate between deaths due to the disease of
interest and deaths due to other causes. In general,
these approaches are not very useful for estimating
prognosis in renal replacement therapy patients due to
lack of comparisons with the general population.
Chronic kidney disease rarely is considered a cause
of death; rather, it commonly is perceived as a factor
that enhances the effect of other causes,4 such as heart
diseases and infections. Thus, it is difficult to deter-
mine the prognosis of patients treated by long-term
dialysis.
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Nordio et alIn cancer registries, this problem was solved by
analyzing relative survival instead of cause-specific or
crude survival. This methodology matches the sur-
vival of patients with a specific malignancy with that
of a standard reference population (usually life tables
of a national or regional population). The relative
survival method relies on the assumption that the
prevalence of the disease is low and has little impact
on overall estimates. Chronic kidney disease fulfills
this assumption because it has negligible impact on
all-cause mortality in the general population. If we
compare the mortality of a cohort of dialysis patients
with that of a matched cohort extracted from the
general population, the only factor that distinguishes
these individuals is dialysis therapy; thus, any mortal-
ity excess observed may be safely attributed to this
factor.
We used the relative survival method to estimate
the decrease in survival directly due to dialysis therapy
in patients of the Italian Dialysis and Transplantation
Registry (IDTR) in order to estimate their prognosis.
Moreover, we tried to identify special subgroups of
patients at high risk of death in order to uncover
which patients should be the focus of research aimed
at ameliorating prognosis.
METHODS
Our analysis is based on data from the IDTR. We performed a
cohort study by selecting all patients starting hemodialysis or
peritoneal dialysis therapy from January 1, 2000, to December 31,
2008, in Italy. Changes in treatment modality or death were
registered until December 31, 2008. Only patients coming from
Italian regions able to provide complete follow-up information
were enrolled, no other eligibility criteria were applied.
Data were collected in accordance with Italian law; the IDTR is
an anonymous collection of regional registries, instituted by re-
gional laws. Informed consent is requested from patients starting
dialysis therapy to allow for data collection within the framework
of the registries and provision of these data to the IDTR in an
anonymous form.
Data considered in this study were date of first treatment, sex,
age (divided into 5 classes: 25, 25-45, 45-65, 65-75, and 75
years), primary kidney disease (grouped into congenital and heredi-
tary disease, diabetes, primary glomerulonephritis, pyelonephritis,
systemic diseases, vascular, unknown, and others), prevailing
dialysis modality (hemodialysis and peritoneal dialysis), kidney
transplant, main comorbid conditions (heart disease, heart failure,
cerebral vascular disease, peripheral vascular disease, diabetes,
chronic lung disease, cancer, and hypertension) defined according
to,5 death, and date of death. The outcome was death from any
cause.
For each patient, survival was calculated from the first dialysis
treatment to death or to December 31, 2008, if alive at the end of
follow-up. If the patient shifted from peritoneal dialysis to hemodi-
alysis therapy or vice versa, he or she was assigned to the
longer-lasting treatment. Successful kidney transplant recipients
and lost patients were censored at the date of the last scheduled
dialysis session.
Information bias could occur for incomplete reporting of the
outcome, leading to overestimation of survival. Therefore, we
compared mortality rates among Italian regions, but did not find
820significant differences. The kidney transplant rate was similar to
the value provided by the National Transplantation Center. The
number of patients lost to follow-up was negligible.
The number of cases in the Italian regions with complete
follow-up in the study period determined sample size.
Relative survival (the ratio of observed survival in the group of
interest to expected survival based on the age- and period-specific
mortality of the general population from which the group was
derived6) can be calculated from the life table of the general
population. In this case, the study sample comprised IDTR partici-
pants who began dialysis therapy in 2000-2008 and the reference
population was the total Italian population of the same age and sex.
The basic assumption is that the expected mortality experienced by
the study sample during a particular period would be the same as
mortality in the general population.
First, the population (l) at the start of each interval in each yearly
cohort and the number of deaths (d) and those lost to follow-up (w)
during the interval were determined. The population at risk (l=  l
– (w/2)) and interval-specific survival (p  1 – [d/l=]) were
estimated by assuming withdrawals and deaths were distributed
evenly over the interval.
Cumulative survival (CP) for a particular interval (i) then was
obtained by the cumulative product of the interval-specific sur-
vival, where the initial cumulative survival (CP[0]) was equal to 1
and CP(i1) CP(i) p(i).
Expected survival probabilities (p*) were obtained from Italian
population life tables7 by multiplication of the published annual
probabilities of survival. The appropriate probability, depending
Table 1. Baseline Characteristics of Dialysis Patients
Demographics No. (%)
Age at initiation of dialysis
25 y 420 (1.50)
25-45 y 2,355 (8.51)
45-65 y 7,356 (26.59)
65-75 y 8,056 (29.12)
75 y 9,487 (34.29)
Sex
Men 17,709 (64.01)
Women 9,933 (35.99)
Type of dialysis
Hemodialysis 23,704 (85.70)
Peritoneal dialysis 3,938 (14.30)
Primary kidney disease
Congenital/inherited 2,033 (7.35)
Diabetic nephropathy 4,943 (17.87)
Primary glomerulonephritis 3,185 (11.51)
Other 1,223 (4.42)
Pyelonephritis and interstitial nephritis 2,294 (8.29)
Systemic diseases 1,495 (5.40)
Unknown or missing 5,597 (20.23)
Vascular nephropathy 6,894 (24.92)
Comorbid conditions
Heart disease 5,497 (19.87)
Cerebral vascular disease 1,927 (6.97)
Peripheral vascular disease 2,895 (10.14)
Diabetes mellitus 6,482 (23.43)
Liver disease 2,337 (8.45)
Cancer 2,669 (9.65)
Hypertension 8,047 (29.09)
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Relative Survival in Dialysis Patientson the sex and age of the patient and year of registration, was
obtained. The probabilities of each follow-up interval were multi-
plied to obtain the expected cumulative survival (CP*).
As a last step, interval-specific and cumulative relative survival
ratios (R and CR) were calculated as the ratios of the observed and
expected interval-specific and cumulative survivals: R  p/p* and
CRCP/CP*.
Excess mortality rate (EMR) could be obtained easily from the
difference between observed (d) and expected deaths (d*) (also
obtained from the Italian life table) divided by person-time at risk
(y) in each interval (i): EMRi di /yi – d*i /yi.
Relative survival and the excess mortality rate are estimated
here according to the Ederer II method,8 in which matched
individuals are treated as being at risk until the corresponding
patient dies or is censored.
In the relative survival model, piecewise constant hazards are
assumed. This treats the number of deaths in each interval as a
Poisson process. In this way, by using a Poisson assumption for the
observed number of deaths, the model may be estimated in the
framework of generalized linear models.9 The exponentiated coef-
ficient estimates of the Poisson model give estimations of the ratios
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Figure 1. The course of observed,
expected, and relative survival during 8
years of follow-up calculated using the
Table 2. Relative Sur
Time on Dialysis No.
Surviv
Observed Expect
3 mo 27,659 0.94 (0.93-0.95) 0.99
6 mo 25,228 0.90 (0.89-0.91) 0.98
1 y 23,337 0.83 (0.82-0.83) 0.97
2 y 19,901 0.72 (0.71-0.73) 0.94
3 y 14,343 0.62 (0.61-0.63) 0.91
4 y 10,016 0.55 (0.54-0.55) 0.88
5 y 6,952 0.47 (0.46-0.48) 0.85
Note: Expected survival corresponds to survival drawn from th
individuals in the general population comparable to dialysis patie
Abbreviation: py, person-year.
aWhen provided, 95% confidence intervals are shown in parenEderer II method.
Am J Kidney Dis. 2012;59(6):819-828between observed and expected deaths and thus may be interpreted
as excess hazard ratios, also known as relative excess risks. This
comparative measure is based solely on the component of risk due
to the exposures because it removes the background risk.10 Good-
ness of fit was assessed using the deviance Pearson 2 statistics.
Statistical analysis was performed using Stata, version 11 (Stata-
Corp, www.stata.com).
RESULTS
The IDTR is a collection of 17 regional registries.
In January 2000 to December 2008, a total of 45,427
individuals started either hemodialysis or peritoneal
dialysis therapy. Because only 8 of the 17 regions
were able to provide complete follow-up data, only
the 27,642 patients belonging to these regions were
considered. They constituted 61% of the full data
set. The percentage of coverage in these 8 regions
was 91%.
2 4 6 8
End of interval
Cumulative observed survival
Cumulative expected survival (Ederer II)
Cumulative relative survival (Ederer II)
per Follow-up Interval
Mortality Rate (/100 py)
Relative Observed Expected Excess
0.95 (0.94-0.95) 24.63 3.15 21.49
0.91 (0.90-0.91) 19.41 3.12 16.30
0.85 (0.84-0.86) 15.66 3.08 12.60
0.77 (0.76-0.77) 13.94 3.04 10.90
0.69 (0.67-0.69) 14.51 3.12 11.39
0.62 (0.61-0.63) 13.42 3.22 10.19
0.56 (0.55-0.56) 14.22 3.28 10.94
eral population. Expected mortality is the mortality of a subset of
s.vival
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these
Nordio et alPatient characteristics are listed in Table 1. Median
age was 70.0 (25th-75th percentile, 58.7-77.7) years,
and 64% of patients were men. During follow-up,
22,756 (82.3%) patients were treated with only hemo-
dialysis; 3,265 (11.8%), with only peritoneal dialysis;
and 1,621 (5.9%), with both hemodialysis and perito-
neal dialysis. There were 11,616 deaths in 74,104
years at risk, determining a crude mortality rate dur-
ing the study period of 15.68 deaths/100 patient-years
(95% confidence interval [CI], 15.39-15.96). Median
survival time was 4.6 (95% CI, 4.5-4.7) years.
Five-year observed and expected survivals were
47.4% and 85.0%, respectively, yielding a relative
survival estimate of 55.6% (95% CI, 54.7%-56.5%).
In other words, survival was less than expected for the
general population by 44.4% (Table 2; Fig 1). Five-
year relative survival was 56.8% (95% CI, 55.6%-
57.9%) in men and 53.5% (95% CI, 52.1%-55.0%) in
women. As listed in Table 3, relative survival largely
Table 3. Five-Year Rela
Age Category No.
Survivala
Observed Expected
25 y 420 0.87 0.998
25-45 y 2,355 0.87 0.994
45-65 y 7,356 0.66 0.964
65-75 y 8,056 0.46 0.881
75 y 9,487 0.27 0.670
Note: Expected survival corresponds to survival drawn from th
individuals in the general population comparable to dialysis patie
Abbreviation: py, person-year.
aWhen provided, 95% confidence intervals are shown in paren
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Years822differed according to age category, being particularly
low in the 2 oldest groups. Five-year relative survival
was 55% (95% CI, 54%-56%) in hemodialysis pa-
tients and 58% (95% CI, 56%-60%) in peritoneal
dialysis patients.
The excess mortality rate did not stay constant over
the time elapsed since dialysis therapy start. As shown
in Table 2 and Fig 2, the excess mortality rate peaks at
21 deaths/100 patient-years at 3 months, decreases to
16 deaths/100 patient-years at 6 months, then reaches
a plateau after 1 year, remaining relatively constant at
around 10 deaths/100 patient-years until year 8. The
decrease in excess mortality rate was similar for men
and women (Fig 3), suggesting that the first-year
excess of deaths is independent of sex.
In Fig 4, mortality rate excess by age category is
shown. It remains relatively stable over time in pa-
tients younger than 65 years, but decreases in the first
6 months in patients older than 65 years.
urvival by Age Category
Mortality Rate (/100 py)
Relative Observed Expected Excess
.87 (0.80-0.92) 3.95 0.05 3.9
.88 (0.86-0.90) 2.92 0.12 2.8
.65 (0.67-0.70) 9.21 0.81 8.4
.52 (0.50-0.54) 14.76 2.76 12.0
.40 (0.38-0.41) 26.07 8.57 17.5
eral population. Expected mortality is the mortality of a subset of
s.
8
Figure 2. Time course of excess mor-
tality rate since dialysis therapy initiation.
Gray region marks 95% confidencetive S
0
0
0
0
0
e gen
nts.6bands.
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Relative Survival in Dialysis PatientsThe excess mortality rate stratified by primary
kidney disease is shown in Fig 5. The increase in
excess mortality in the earliest period after starting
dialysis therapy was observed in mainly 2 diagnostic
categories: systemic disease and miscellaneous catego-
ries. In the systemic disease category, 39% of pa-
tients had multiple myeloma, and in the miscella-
neous category, 33% of patients had kidney
neoplasms; thus, many early deaths occur in pa-
tients affected by cancer.
The excess mortality time trend differed, showing
an initial peak with a rapid decrease in hemodialysis
and a modest progressive increase in peritoneal dialy-
sis (Fig 6).
10
15
20
25
Ev
en
ts
 p
er
 1
00
 p
at
ie
nt
−y
ea
r
0
Figure 3. Excess mortality rate strati-
fied by sex.
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>= 75Am J Kidney Dis. 2012;59(6):819-828Excess mortality was modeled using Poisson regres-
sion in order to examine the possible determinants of
excess hazard ratios, also known as relative excess
risks. Table 4 lists unadjusted and adjusted relative
excess risks. Patients who survived the first year had
lower relative excess risk. Older age, systemic dis-
eases, and diabetes had the strongest association with
excess mortality. As listed in Table 5, which reports
the interaction between follow-up period and type of
dialysis, peritoneal dialysis was associated with lower
relative excess risk in only the first year of treatment,
but since the second year, relative excess risk was
higher than in hemodialysis.
2 4 6 8
Years
Male Female
8
Figure 4. Excess mortality rate strati-
fied by age category. Abbreviation: py,6
44
74patient-year.
823
Nordio et alThe assessed goodness of fit did not show evidence
of lack of fit.
DISCUSSION
Relative survival is the standard measure of sur-
vival in cancer registries11,12 and has been proposed
for use in other chronic diseases, such as cardiovascu-
lar disease13 and diabetes.14 Relative survival may be
understood as the survival of a population affected by
a particular disease under study, adjusted for all other
competing causes of death. Dialysis patients, as part
of the general population, are not isolated from the
lifestyle risks and environmental and infectious deter-
minants of diseases affecting the community as a
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Figure 6. Excess mortality rate strati-
fied by type of dialysis. Abbreviations:
HD, hemodialysis; PD, peritoneal dialy-
sis.
824whole. The possible risk factors relevant for dialysis
patients may be split into 2 components: the back-
ground mortality typical of the population plus the
excess due to dialysis. Some parallels exist between
dialysis patients and patients with cancer: both are
affected by chronic diseases, both have extended
survival data collected about them, and for each of
these 2 groups, there are annual registries that make
such data available. This similarity encouraged us to
broaden the use of relative survival methodology to
the field of renal replacement therapy.
By using this methodology, we were able to esti-
mate the prognosis of dialysis patients receiving long-
term dialysis, showing that they experience survival
8
IC
LAR
Figure 5. Excess mortality rate ac-
cording to primary kidney disease. Abbre-
viations: CONG or INHER, congenital or
inherited kidney diseases; DIAB, dia-
betic nephropathy; GN, primary glomeru-
lonephritis; OTHER, other kidney dis-
eases; PN and IN, pyelonephritis and
interstitial nephritis; py, patient-year;
SYSTEMIC, systemic diseases; UNKN
or MISS, unknown or missing diagnosis;
VASCULAR, vascular kidney disease.
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Relative Survival in Dialysis Patientsof 55% at 5 years in comparison to the general
population. To our knowledge, this is the first time
that dialysis patients’ prognosis has been measured by
determining its relationship to background survival.
This method offers additional advantages because
relative survival makes dialysis patients’ outcomes
comparable between different countries and health
care systems and between different chronic diseases,
allowing adjustment for the background mortality of
the source population.15 For example, the US Renal
Data System (USRDS) reports a higher mortality rate
than European or Japanese registries, a difference that
might be due at least in part to the respective source
Table 4. Unadjusted and Adjusted Rel
Variable Deaths
Time elapsed since dialysis initiation
1 y 4,495
2 y 2,372
3 y 1,756
4 y 1,132
5 y 811
6 y 562
7 y 280
8 y 155
Age category
25 y 24
25-45 y 209
45-65 y 1,968
65-75 y 3,689
75 y 5,673
Sex
Men 6,996
Women 4,267
Primary renal disease
Congenital/inherited 414
Diabetes 2,334
Primary glomerulonephritis 721
Others 548
Pyelonephritis 935
Systemic diseases 869
Unknown 2,444
Vascular diseases 3,345
Comorbid conditions
Ischemic heart disease 1,561
Heart failure 1,084
Cerebral vascular disease 1,004
Peripheral vascular disease 1,425
Liver disease 394
Cancer 1,169
Hypertension 2,591
Note: RER of death with 95% confidence intervals. RER is anal
using Poisson regression.
Abbreviation: RER, relative excess risk.
aSignificant RERs (P 0.05).population: Japan has the highest life expectancy in
Am J Kidney Dis. 2012;59(6):819-828the world, and almost all Western European countries
have a higher life expectancy than the United States.16
The 5-year relative survival of dialysis patients is
lower than that reported for regional breast cancer
(84%), regional colon cancer (69.5%), and regional
kidney cancer (62.7%), but higher than that for chronic
heart failure (35%) and regional lung cancer (24%).17
It is possible to rank the severity of different chronic
diseases and compare their prognosis (Fig 7). From
this perspective, dialysis patients need at least as
much attention as cancer patients from health authori-
ties and public opinion.
An interesting characteristic shown by the relative
Excess Risk by Patient Characteristics
tients Unadjusted RER Adjusted RER
,659 1.00 (reference) 1.00 (reference)
,901 0.67a (0.62-0.71) 0.74a (0.68-0.81)
,343 0.70a (0.65-0.75) 0.57a (0.52-0.62)
,016 0.63a (0.57-0.69) 0.48a (0.44-0.52)
,952 0.67a (0.61-0.74) 0.49a (0.45-0.54)
,565 0.77a (0.68-0.86) 0.46a (0.42-0.51)
,867 0.58a (0.49-0.69) 0.49a (0.43-0.55)
,597 0.67a (0.54-0.82) 0.58a (0.51-0.66)
410 1.00 (reference) 1.00 (reference)
,355 1.21 (0.79-1.86) 1.26 (0.82-1.94)
,356 3.37a (2.24-5.09) 3.23a (2.14-4.88)
,056 5.84a (3.88-8.78) 5.09a (3.37-7.69)
,482 8.81a (5.85-13.25) 7.25a (4.8-10.95)
,706 1.00 (reference) 1.00 (reference)
,953 1.15a (1.09-1.21) 1.08a (1.03-1.14)
,033 1.00 (reference) 1.00 (reference)
,943 4.37a (3.69-5.16) 2.91a (2.50-3.38)
,185 1.20 (0.98-1.46) 1.19a (1.00-1.42)
,223 4.17a (3.44-5.05) 2.78a (2.34-3.30)
,293 2.89a (2.41-3.46) 2.02a (1.71-2.37)
,495 6.91a (5.79-8.25) 5.93a (4.29-5.90)
,594 3.45a (2.91-4.09) 2.38a (2.05-2.77)
,893 3.81a (3.22-4.50) 2.25a (1.94-2.62)
,256 1.24a (1.16-1.32) 1.08a (1.01-1.17)
,239 1.33a (1.23-1.43) 1.17a (1.08-1.26)
,927 1.33a (1.23-1.44) 1.14a (1.05-1.24)
,804 1.33a (1.24-1.43) 1.18a (1.09-1.27)
923 1.08 (0.96-1.22) 1.15a (1.02-1.30)
,337 1.32a (1.22-1.42) 1.13a (1.04-1.21)
,045 0.64a (0.60-0.67) 0.60a (0.56-0.63)
s to relative risk ratio when excess mortality ratio models are builtative
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Nordio et aloff over time. This implies that individuals receiving
dialysis are never cured (at least in a statistical sense)
because it is inevitable that they will die earlier than
matched individuals in the general population. Con-
trary to what happens in neoplastic diseases, for
which a proportion of patients are cured, dialysis
patients never heal and thus no cure model may be
proposed.
When modeling relative survival, we try to estimate
directly the excess mortality experienced by patients
receiving dialysis compared with that of the general
population, thereby obtaining an estimate of net sur-
vival. In the first year of dialysis therapy, mortality is
exceedingly high, identifying a subgroup of patients
who do not benefit from it. These patients make up
Table 5. Relative Excess Risk by Time Elapsed Since
Treatment Start for Peritoneal Dialysis Patients
Time Elapsed Since Dialysis Initiation RER (95% CI)
1 y 0.65a (0.57-0.74)
2 y 2.13a (1.74-2.59)
3 y 2.35a (1.89-2.93)
4 y 2.62a (2.03-3.39)
5 y 2.79a (2.06-3.79)
6 y 2.24a (1.51-3.31)
7 y 2.69a (1.49-4.84)
8 y 2.15 (0.98-4.71)
Note: Values for peritoneal dialysis patients are shown; hemo-
dialysis patients constitute the reference group. RER is analo-
gous to relative risk ratio when excess mortality ratio models are
built using Poisson regression.
Abbreviations: CI, confidence interval; RER, relative excess
risk.
aSignificant RERs (P 0.05).
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Prostate cancer826about 15% of the observed population. That dialysis
patients undergo early high mortality during renal
replacement therapy has been reported previously,18-21
but its description as mortality rate excess provides a
more accurate measure because it is independent of
the incidence of the disease. In many dialysis regis-
tries, the early mortality excess emerges only partially
because these registries exclude the first 3 months of
renal replacement therapy.1 It is estimated that pa-
tients not registered in the USRDS in the first 3
months are about 6% of the incident population.19
After the first year, there is a decrease in risk of excess
mortality, an observation that is preserved even after
adjustment for age, primary kidney disease, and comor-
bid conditions.
Early excess mortality has been reported in patients
undergoing hemodialysis treatment only, likely due to
selection bias because the most severely affected
patients are not accepted into a peritoneal dialysis
program.22 However, evidence is lacking that perito-
neal dialysis is unsuitable for the sickest patients.
Although (accounting for background mortality) rela-
tive excess risk is lower in the first year of peritoneal
dialysis compared with hemodialysis therapy, it be-
comes at least twice that of hemodialysis from the
second year onward. Thus, our comparison shows
results similar to the CHOICE (Choices for Healthy
Outcomes in Caring for ESRD) Study23; namely, an
initial advantage survival given by peritoneal dialysis
in the first year, followed by the hemodialysis advan-
tage survival up to the seventh year. However, this
result must be interpreted very cautiously because the
censoring due to kidney transplant may not be uninfor-
mative, as required in survival analysis. Because
80 100
%)
Figure 7. Comparison of 5-year rela-
tive survival of most important cancers
with long-term dialysis and heart failure.
Diseases are sorted by severity of prog-ival (
nosis.
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Relative Survival in Dialysis Patientsabout 15% of peritoneal dialysis patients underwent
transplant versus only 9% of hemodialysis patients,
the mortality of peritoneal dialysis patients could have
been overestimated.24
The impact of age on excess mortality risk is very
relevant. Having taken into account that this measure
is already adjusted for background mortality due to
age itself, we showed that the relative excess risk of
older patients is much higher. This means that the
outcome of dialysis patients is more severe in fragile
individuals.
Modeling of the excess mortality rate confirms
results of the univariate analysis: the strongest predic-
tors of excess mortality were age and some primary
kidney diseases. The other covariates, such as sex and
comorbid conditions, even if statistically significant,
have only a marginal effect. It is worth emphasizing
that women have a higher risk of death than men if
background mortality is considered. This is another
example of reverse epidemiology that may be found
in dialysis patients.
There are 3 major limitations to this study. First, the
cohort of patients available for our analysis makes up
only about half the Italian patients who began receiv-
ing dialysis in the selected period. However, this
pitfall is minimized by our taking into consideration
only the Italian regions able to provide full data sets.
Mortality rates were very similar and consistent within
regions; thus, results probably are generalizable to the
entire nation. Second, at least 2 regions had coverage
less than 70% and one of them contributed substan-
tially to the number of patients, thus possibly biasing
results in an indeterminate way. However, a previous
analysis performed on a single region with coverage
near 100% gave similar results (Nordio M, Antonucci
F, unpublished data), suggesting that the bias, if pres-
ent, should not be critical. Third, although the relative
survival method allows us to override the competing
risks derived from different causes of death that
compete each other, it cannot treat competing risks
arising from changes in renal replacement modality;
for example, death on dialysis therapy prevented by
kidney transplant.
In conclusion, this study emphasizes the usefulness
of relative survival methodology in dialysis patients.
This measure allows estimation of the prognosis of
the disease and comparison of its severity with other
chronic diseases. It provides a useful tool for compar-
ing outcomes between dialysis registries because it
takes into account the characteristics of the source
population. The excess mortality rate seems a suitable
measure to describe the trend of mortality in dialysis
populations in a much more sensitive and informative
way than that provided by the simple assessment of
proportion of survivors. Because to our knowledge
Am J Kidney Dis. 2012;59(6):819-828this is the first study that uses these measures in a
dialysis registry, the worth of the methodology cannot
be validated fully, but we hope that further studies will
exploit its potential.
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